Nova TheraNostics is managed by an experienced group of industry veterans with an extensive history of start-up, big pharma, scientific, and radiologic experience. We operate with a very efficient operational structure by existing in a predominantly virtual manner keep expenses and infrastructure costs to a minimum
Dr. Reddington was the s Chief Operating Officer of Ophiuchus Technologies AG, a Swiss based stem cell company. Before joining Ophiuchus, he was COO of Cambridge Biomedical, MA (USA), and has started and managed several private and public biotech companies for almost 25 years. Previously Dr Reddington served as President and CEO of Sirtex Medical, Inc., the US division of the Australian publicly traded company Sirtex Medical Group Ltd. (ASX:SIR), where he reorganized and revitalized the US division that accounted for 80% of the corporation’s Aus$66 million in revenue. Before Sirtex, he was COO and Senior VP of R&D for the publicly traded company Valentis Inc., where he played a key role in transitioning Valentis’ clinical focus from gene therapy to poloxamer-based therapeutics for cardiovascular disease. During his tenure he helped secure $30 million in new equity financing, as well as licensing and supply agreements valued up to $500 million; he was also responsible for selling off all non-critical assets to facilitate a reverse merger, and spun out the manufacturing division as an independent business unit. Previously, Dr Reddington founded DiagXotics Inc. and led it to become the world leader in disease diagnosis for the $52 billion global aquaculture market. He received his BA from Rice University, his MA from the University of Texas, Arlington and his DVM and PhD from Washington State University.
Dr. Ho is the Milo Gibaldi Endowed Professor of Pharmaceutics and Director of the DNA Sequencing and Gene Analysis Center at the University of Washington. He is the inventor of the NTN platform technology and a co-founder of NTN. Rodney also holds appointments at Clinical Pharmacology, Fred Hutchinson Cancer Research Center, the Center for AIDS and STD Research, the Center for Human Development and Disability, the Center for Ecogenetics at the University of Washington, and the Washington National Primate Research Center. He is an elected Fellow and Chair of the American Association for the Advancement of Sciences. He is also an electded Fellow of the American Association of Pharmaceutical Scientists (AAPS). Dr. Ho’s accomplishments include six patents, over 90 peer-reviewed publications, 20 book chapters and he has edited two books. Rodney has received numerous honors, including AAPS’s Biotechnology lifetime Research Achievement and Paul Dawson lifetime contribution to education and research in Biotechnology awards, and has served as a consultant to pharmaceutical and biotechnology companies for over 20 years.
Dr. Schmiedl is a board-certified radiologist specializing in MR imaging, ultrasound, CT and diagnostic radiology. Dr. Schmiedl, who has more than 30 years experience in his field, has given multiple lectures at national and international meetings and has published numerous papers on MR and CT imaging and contrast agents. He completed a fellowship magnetic resonance imaging and contrast media at the University of California, a fellowship in body imaging and ultrasound at the University of Washington, and a residency in radiology at the University of Tübingen. Before his work at the University of Tübingen, Dr. Schmiedl completed a rotating internship in internal medicine, surgery and anesthesiology at the University of Heidelberg, shared a general practice and served as an army physician. Following his tenure as Professor of Radiology and Director of Abdominal Imaging at the University of Washington he joined Seattle Radiologists at Swedish Medical Center in private practice and currently holds a position as Clinical Professor of Radiology at the University of Washington.
With over 30 years experience in the Pharma industry who has raised over $200 million in equity with proven success in business partnering and operations. Currently, Mr Philips is the President of Kineta Inc, a immuno-oncology focused biotech company based in Seattle. He started his career with Bristol Myers in the US, prior to spending 14 years with Schering Plough (now Merck) in a variety of leadership roles including Global marketing, Hospital Business Unit head in Canada, General Manager Thailand, and General Manager Australia/New Zealand. He joined Berlex (Schering Ag) in 2004 and led the Oncology business in he US, when Bayer acquired Schering Ag, he was subsequently named head of the combined US oncology organization, with approximate 150 staff. He was appointed President of Cell Therapeutics (now CTI Biopharma) where for 4 years he oversaw the commercial and clinical operations where he was active in business development and corporate operations in the US and EU. Mr Philips has been working with a variety of small and emerging life science companies, we founded several life science companies. As a senior executive and officer in publically traded companies, he has led commercial and clinical teams in the US and abroad. He serves as a Board member and an advisory board member for several life science start-up companies. He received his BSc in Business and Administration and his MBA from The Ohio State University.
Nova TheraNostics Inc
Nova TheraNostics Inc 4000 Mason Rd, Suite 302 Suite 302, Fluke Hall Seattle, WA 98195 US
Copyright © 2020 Nova TheraNostics Inc - All Rights Reserved.
Powered by GoDaddy Website Builder